| scholarly article | Q13442814 |
| P2093 | author name string | Zhang B | |
| Ratner RE | |||
| Kim DD | |||
| Nielsen LL | |||
| Bicsak TA | |||
| Poon T | |||
| Brodows RG | |||
| Maggs D | |||
| Stonehouse AH | |||
| P2860 | cites work | Metformin: An Update | Q22241145 |
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| Pharmacologic therapy for type 2 diabetes mellitus | Q33716414 | ||
| Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity | Q34416085 | ||
| Oral antihyperglycemic therapy for type 2 diabetes: scientific review | Q34492673 | ||
| Clinical practice. Initial management of glycemia in type 2 diabetes mellitus | Q34979136 | ||
| Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. | Q35018510 | ||
| Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes | Q35618856 | ||
| Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans | Q35844598 | ||
| Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes. | Q35941128 | ||
| The dyslipidemia of diabetes mellitus: giving triglycerides and high-density lipoprotein cholesterol a higher priority? | Q36064135 | ||
| Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes | Q42169660 | ||
| Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro | Q43586628 | ||
| Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study | Q43919658 | ||
| Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context | Q44790424 | ||
| Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study | Q45074002 | ||
| Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight | Q45200771 | ||
| Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes | Q46689486 | ||
| Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats | Q47238177 | ||
| Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes. | Q51547881 | ||
| Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. | Q51551544 | ||
| Repaglinide versus glyburide: a one-year comparison trial. | Q51562922 | ||
| Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. | Q51586347 | ||
| P433 | issue | 4 | |
| P921 | main subject | metformin | Q19484 |
| patient | Q181600 | ||
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 419-428 | |
| P577 | publication date | 2006-07-01 | |
| P1433 | published in | Diabetes, Obesity and Metabolism | Q5270109 |
| P1476 | title | Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus | |
| P478 | volume | 8 |
| Q38020941 | A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes |
| Q56967676 | A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus |
| Q33268721 | A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice |
| Q42846868 | A placebo‐controlled trial of exenatide twice‐daily added to thiazolidinediones alone or in combination with metformin |
| Q37403218 | A review of exenatide as adjunctive therapy in patients with type 2 diabetes |
| Q26801346 | Adverse Effects of GLP-1 Receptor Agonists |
| Q50801252 | Approaches to help people with diabetes overcome barriers for improved health outcomes. |
| Q37960073 | Approaches to the pharmacological treatment of obesity |
| Q35074194 | Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes |
| Q51744991 | Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption. |
| Q37677036 | Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus |
| Q46558640 | Beyond glycemic control: the effects of incretin hormones in type 2 diabetes |
| Q37199333 | Beyond insulin replacement: addressing the additional needs of the diabetes patient |
| Q37768338 | Bowels control brain: gut hormones and obesity |
| Q28741419 | Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes |
| Q46760415 | Clinical experience with exenatide in predominantly Asian and Pacific Islander patients with type 2 diabetes |
| Q38213037 | Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure |
| Q34182476 | Effective weight loss after treatment with a glucagon-like peptide-1 receptor agonist in a morbidly obese and diabetic patient before bariatric surgery: a case report |
| Q36584204 | Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. |
| Q33785151 | Effects of exenatide in a morbidly obese patient with type 2 diabetes |
| Q35227453 | Effects of glucagon-like peptide-1 agents on left ventricular function: systematic review and meta-analysis |
| Q37683441 | Effects of metformin on hyperglycemia in an experimental model of tacrolimus- and sirolimus-induced diabetic rats |
| Q28286240 | Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial |
| Q28088578 | Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus |
| Q34381281 | Emerging treatment options for type 2 diabetes |
| Q38095231 | Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors |
| Q39571328 | Evaluating the cost-effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK. |
| Q36897192 | Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom |
| Q38219482 | Evidence-based practice use of incretin-based therapy in the natural history of diabetes |
| Q36877205 | Evolution of exenatide as a diabetes therapeutic |
| Q33664114 | Exenatide Use in the Management of Type 2 Diabetes Mellitus |
| Q37049686 | Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity |
| Q37119264 | Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction |
| Q46564566 | Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner |
| Q42660412 | Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes |
| Q36670931 | Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks |
| Q34144380 | Exenatide once weekly: clinical outcomes and patient satisfaction. |
| Q40964981 | Exenatide: a new promising antidiabetic agent |
| Q33794098 | GLP-1 for type 2 diabetes |
| Q39255303 | GLP-1 receptor agonists in NAFLD. |
| Q37049674 | GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors |
| Q37598258 | Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors |
| Q35778284 | Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity |
| Q37057996 | Gut hormones as potential new targets for appetite regulation and the treatment of obesity |
| Q37760515 | Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects |
| Q36786998 | Incretin-based therapies for type 2 diabetes: clinical utility |
| Q37316259 | Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. |
| Q38008596 | Incretins as a novel therapeutic strategy in patients with diabetes and heart failure. |
| Q37082698 | Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering |
| Q38885174 | Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists |
| Q38216039 | Long-term tolerance and efficacy of adjunctive exenatide therapy on glycaemic control and bodyweight in type 2 diabetes: a retrospective study from a specialist diabetes outpatient clinic |
| Q37613264 | Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis |
| Q37102861 | Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes |
| Q86694994 | Metabolic and hormonal consequences of two different meals after a moderate intensity exercise bout in obese prepubertal children |
| Q36423076 | Metformin and its clinical use: new insights for an old drug in clinical practice. |
| Q37262966 | Metformin therapy and clinical uses |
| Q46457054 | Multidisciplinary interventions: mapping new horizons in diabetes care |
| Q35153309 | New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies |
| Q33607971 | Obesity treatment: novel peripheral targets |
| Q28287325 | Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial |
| Q37069180 | Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities |
| Q37260330 | Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. |
| Q26766485 | Pancreatic regulation of glucose homeostasis |
| Q46220335 | Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus |
| Q37594792 | Pharmacotherapy of hyperglycemia |
| Q28076059 | Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association |
| Q36391466 | Potential use of exenatide for the treatment of obesity |
| Q37857695 | Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes |
| Q24235718 | Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus |
| Q24240522 | Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus |
| Q24244739 | Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus |
| Q37162889 | Role of metformin for weight management in patients without type 2 diabetes |
| Q31066859 | Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program |
| Q34133324 | Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide |
| Q51382645 | Should the metabolic syndrome patient with prediabetes be offered pharmacotherapy? |
| Q30401145 | Tackling obesity: new therapeutic agents for assisted weight loss. |
| Q37270524 | Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors |
| Q37812687 | The Evidence for Medical Nutrition Therapy for Type 1 and Type 2 Diabetes in Adults |
| Q28078225 | The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review |
| Q37992253 | The design of the liraglutide clinical trial programme |
| Q42054096 | The evolving world of GLP-1 agonist therapies for type 2 diabetes |
| Q30399340 | The pharmacological treatment and management of obesity |
| Q81630853 | The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects |
| Q37606032 | The usefulness of a Mediterranean-based diet in individuals with type 2 diabetes |
| Q37682561 | Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes |
| Q59805368 | Topiramate and Metformin Are Effective Add-On Treatments in Controlling Antipsychotic-Induced Weight Gain: A Systematic Review and Network Meta-Analysis |
| Q37609829 | Treating type 2 diabetes: incretin mimetics and enhancers |
| Q46519581 | Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin |
| Q34159414 | Weight Considerations in Pharmacotherapy for Type 2 Diabetes |
Search more.